Abstract
Since the first successful cord blood transplant was performed in 1988 there has been a gradual increase in the use of cord blood for hemopoietic stem cell transplantation. Worldwide, over 8,000 unrelated cord blood transplants have been performed with the majority being for children with hemopoietic malignancies. Transplantation for adults has increased but is limited by the low number of nucleated cells and CD34+ cells within a single cord blood collection. Cord blood hemopoietic stem cells are more primitive than their adult counterparts and have high proliferative potential. Cord blood ex vivo expansion is designed to improve transplant outcomes by increasing the number of hemopoietic stem cells with long term repopulating potential and their differentiated progeny. However, despite a large amount of research activity during the last decade, this aim has not been realized. Herein we discuss the rationale for this approach; culture methods for ex vivo expansion, ways to assess the functional capacity of ex vivo generated hemopoietic stem cells and clinical outcomes following transplantation with ex vivo expanded cord blood.
Keywords: Stem cells, cord blood, ex vivo expansion, transplantation
Current Stem Cell Research & Therapy
Title: Expansion of Umbilical Cord Blood for Clinical Transplantation
Volume: 2 Issue: 4
Author(s): David N. Haylock and Susan K. Nilsson
Affiliation:
Keywords: Stem cells, cord blood, ex vivo expansion, transplantation
Abstract: Since the first successful cord blood transplant was performed in 1988 there has been a gradual increase in the use of cord blood for hemopoietic stem cell transplantation. Worldwide, over 8,000 unrelated cord blood transplants have been performed with the majority being for children with hemopoietic malignancies. Transplantation for adults has increased but is limited by the low number of nucleated cells and CD34+ cells within a single cord blood collection. Cord blood hemopoietic stem cells are more primitive than their adult counterparts and have high proliferative potential. Cord blood ex vivo expansion is designed to improve transplant outcomes by increasing the number of hemopoietic stem cells with long term repopulating potential and their differentiated progeny. However, despite a large amount of research activity during the last decade, this aim has not been realized. Herein we discuss the rationale for this approach; culture methods for ex vivo expansion, ways to assess the functional capacity of ex vivo generated hemopoietic stem cells and clinical outcomes following transplantation with ex vivo expanded cord blood.
Export Options
About this article
Cite this article as:
Haylock N. David and Nilsson K. Susan, Expansion of Umbilical Cord Blood for Clinical Transplantation, Current Stem Cell Research & Therapy 2007; 2 (4) . https://dx.doi.org/10.2174/157488807782793745
DOI https://dx.doi.org/10.2174/157488807782793745 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Viral and Non-Viral Approaches for Transient Delivery of mRNA and Proteins
Current Gene Therapy Genetically Modified Dendritic Cells for Cancer Immunotherapy
Current Gene Therapy Significant Role of MUC1 in Development of Resistance to Currently Existing Anti-cancer Therapeutic Agents
Current Cancer Drug Targets Haploidentical Stem Cell Transplantation in Childhood
Current Cancer Therapy Reviews Advances in Imaging Gene-Directed Enzyme Prodrug Therapy
Current Pharmaceutical Biotechnology Noscapine and its Analogs as Chemotherapeutic Agent: Current updates
Current Topics in Medicinal Chemistry Regulation of EMT by Notch Signaling Pathway in Tumor Progression
Current Cancer Drug Targets Therapeutic Perspectives on Pancreatic Cancer
Current Cancer Drug Targets Radiation Therapy in the Management of Lung Cancer
Current Respiratory Medicine Reviews Prostate-Apoptosis-Response-Gene-4: Biological Properties and their Potential Therapeutic Exploitation in Hematological Malignancies
Letters in Drug Design & Discovery The Correlation between EGFR and Androgen Receptor Pathways: A Novel Potential Prognostic Marker in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry Lessons Learned from Two Decades of Clinical Trial Experience in Gene Therapy for Fanconi Anemia
Current Gene Therapy Relevance of Breast Cancer Resistance Protein to Brain Distribution and Central Acting Drugs: A Pharmacokinetic Perspective
Current Drug Metabolism Desferrioxamine as Immunomodulatory Agent During Microorganism Infection
Current Pharmaceutical Design Signal Transduction through JAK-STAT and NF-κB Regulated Pim-1 Kinase: Novel Target for Anticancer Leads
Current Signal Transduction Therapy Application of the Phage Display Technology for the Development of Peptide- mediated Drug Delivery Systems through the Blood-Brain Barrier
Current Pharmaceutical Biotechnology The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine Plasma Pharmacokinetics of Antimicrobial Agents in Critically Ill Patients
Current Clinical Pharmacology Roles of Epithelial-Mesenchymal Transition in Cancer Drug Resistance
Current Cancer Drug Targets Mechanisms of Resistance to Imatinib in CML Patients: A Paradigm for the Advantages and Pitfalls of Molecularly Targeted Therapy
Current Cancer Drug Targets